Vascular Biogenics Ltd. (VBLT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vascular Biogenics Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
October 01, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Dror Harats | Chief Executive Officer & Director | 444,333 | 1957 |
| Samuel Backenroth | Chief Financial Officer | 410,000 | 1984 |
| Advocate Ayelet Horn | Gen. Counsel | 0 | 1971 |
| Deborah Scott | Managing Director of Financial Communications | 0 | N/A |
| Erez Feige | Senior Vice President of Bus. Operations | 0 | 1974 |
| Eyal Breitbart | Senior Vice President of Research & Operations | 0 | 1967 |
| Naamit Sher | Senior Vice President of Drug Devel. & Regulatory Affairs | 0 | 1954 |
| Tami Rachmilewitz | Senior Vice President of Clinical Devel. | 0 | 1971 |
| Yael Cohen | Medical Director | 0 | 1963 |
Description
Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.
